镓-68前列腺特异性膜抗原正电子发射断层显像在晚期前列腺癌中的诊断效用、敏感性、特异性及前列腺特异性膜抗原亲和病灶分布更新:系统评价与Meta分析
该系统评价与Meta分析纳入37篇文献共4790例患者,评估68Ga-PSMA PET在生化复发及晚期前列腺癌中的诊断效能。生化复发患者阳性率随PET前PSA水平升高而增加,PSA 0-0.19、0.2-0.49、0.5-0.99、1-1.99、≥2ng/ml组阳性率分别为33%、45%、59%、75%、95%。淋巴结分析敏感度75%、特异度99%。
要点
- 生化复发患者68Ga-PSMA PET阳性率随PET前PSA升高而增加,≥2ng/ml组达95%。
- 生化复发后前列腺床阳性率根治性前列腺切除组22% vs 放疗组52%。
- 淋巴结分析敏感度75%、特异度99%。
核心结论
- 68Ga-PSMA PET可改善生化复发转移灶检出,尤其在PET前PSA>0.2ng/ml(33%)和0.2-0.5ng/ml(45%)的低水平时。
- 汇总数据Meta分析显示68Ga-PSMA PET具有良好敏感度和特异度。
- 该分析强调原发与生化复发背景下PSMA PET显示不同解剖转移模式。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、ScienceDirect、Cochrane Libraries和Web of Science数据库(2018年7月),遵循PRISMA声明。
- 采用QUADAS-2工具进行质量评价,比例Meta分析采用随机效应模型,汇总敏感度和特异度通过双变量层次回归模型拟合。
- 共纳入37篇文献、4790例患者。
主要发现
- 生化复发患者PET前PSA 0-0.19、0.2-0.49、0.5-0.99、1-1.99、≥2ng/ml组阳性率分别为33%、45%、59%、75%、95%。
- Gleason评分≤7与≥8组阳性率无显著差异。
- 淋巴结分析敏感度75%、特异度99%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is becoming increasingly more important in guiding local and systemic treatment. Gallium-68 prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has increasingly been utilised globally to assess the local and metastatic burden of prostate cancer, typically in biochemically recurrent or advanced disease. Following our previous meta-analysis, a high-volume series has been reported highlighting the utility of 68Ga-PSMA PET in this setting. OBJECTIVE: To perform a systematic review and meta-analysis to update reported predictors of positive 68Ga-PSMA PET according to prior therapy and proportion of positivity in various anatomical locations with sensitivity and specificity profiles. EVIDENCE ACQUISITION: We performed critical reviews of MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries, and Web of Science databases in July 2018 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Quality assessment was performed using Quality Assessment if Diagnostic Accuracy Studies-2 tool. Meta-analyses of proportions were performed using a random-effect model. Summary sensitivity and specificity values were obtained by fitting bivariate hierarchical regression models. EVIDENCE SYNTHESIS: A total of 37 articles including 4790 patients were analysed. For patients with biochemical recurrence, positive 68Ga-PSMA PET scans increased with higher pre-PET prostate-specific antigen (PSA) levels. For PSA categories 0-0.19, 0.2-0.49, 0.5-0.99, 1-1.99, and ≥2ng/ml, the percentages of positive scans were 33%, 45%, 59%, 75%, and 95%, respectively. No significant differences in positivity were noted between Gleason sums ≤7 and ≥8. Significant differences in positivity after biochemical recurrence in the prostate bed were noted between radical prostatectomy (22%) and radiotherapy (52%) patients. On per-node analysis, high sensitivity (75%) and specificity (99%) were observed. CONCLUSIONS: Ga-68-PSMA PET improves detection of metastases with biochemical recurrence, particularly at low pre-PET PSA levels of >0.2ng/ml (33%) and 0.2-0.5ng/ml (45%). Ga-68-PSMA-PET produces favourable sensitivity and specificity profiles on meta-analysis of pooled data. This analysis highlights different anatomic patterns of metastatic spread according to PSMA PET in the primary and biochemically recurrent settings. PATIENT SUMMARY: Gallium-68 prostate-specific membrane antigen positron emission tomography is now an established imaging technique that has been developed in response to inadequacies in standard of care imaging modalities to improve the detection of metastatic disease in prostate cancer, particularly in the setting of disease recurrence. To date, this imaging modality in the setting of primary staging is controversial, given the paucity of data. In light of the growing body of evidence, we summarised the data to date to provide clinicians with an overview of this imaging modality.
引用
- Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2019. PMID: 30773328. doi:10.1016/j.eururo.2019.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。